EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 29 / No 6-7 (Juin–Juillet 2013) Med Sci (Paris), 29 6-7 (2013) 597-606 References
Free Access
Issue
Med Sci (Paris)
Volume 29, Number 6-7, Juin–Juillet 2013
Page(s) 597 - 606
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013296012
Published online 12 July 2013
  1. Vassort G, Fauconnier J. Les canaux TRP (transient receptor potential). Med Sci (Paris) 2008 ; 24 : 163–168. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Kedei N, Szabo T, Liles J, et al. Analysis of the native quaternary structure of vanilloid receptor 1. J Biol Chem 2001 ; 276 : 28613–28619. [CrossRef] [PubMed] [Google Scholar]
  3. Nagy I, Sántha P, Jancsó G, et al. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004 ; 500 : 351–369. [CrossRef] [PubMed] [Google Scholar]
  4. Hwang SW, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000 ; 97 : 6155–6160. [CrossRef] [Google Scholar]
  5. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 2004 ; 271 : 1814–1819. [CrossRef] [PubMed] [Google Scholar]
  6. Rohacs T, Thyagarajan B, Lukacs V. Phospholipase C mediated modulation of TRPV1 channels. Mol Neurobiol 2008 ; 37 : 153–163. [CrossRef] [PubMed] [Google Scholar]
  7. Patwardhan AM, Jeske NA, Price TJ, et al. The cannabinoid WIN 55, 212–2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci USA 2006 ; 103 : 11393–11398. [CrossRef] [Google Scholar]
  8. Rosenbaum T, Gordon-Shaag A, Munari M, et al. Ca2+/calmodulin modulates TRPV1 activation by capsaicin. J Gen Physiol 2004 ; 123 : 53–62. [CrossRef] [PubMed] [Google Scholar]
  9. Szolcsányi J, Pintér E, Helyes Z, et al. Inhibition of the function of TRPV1-expressing nociceptive sensory neurons by somatostatin 4 receptor agonism: mechanism and therapeutical implications. Curr Topics Med Chem 2011 ; 11 : 2253–2263. [CrossRef] [Google Scholar]
  10. Endres-becker J, Heppenstall PA, Mousa SA, et al. Opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol Pharmacol 2007 ; 71 : 12–18. [CrossRef] [PubMed] [Google Scholar]
  11. Willis WD. The role of TRPV1 receptors in pain evoked by noxious thermal and chemical stimuli. Exp Brain Res 2009 ; 196 : 5–11. [CrossRef] [PubMed] [Google Scholar]
  12. Calvino B. L’hypersensibilité à la chaleur au cours de l’inflammation : le rôle du récepteur TRPV1. Med Sci (Paris) 2003 ; 19 : 649–651. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Geppetti P, Materazzi S, Nicoletti P. The transient receptor potential vanilloid 1: role in airway inflammation and disease. Eur J Pharmacol 2006 ; 533 : 207–214. [CrossRef] [PubMed] [Google Scholar]
  14. Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV1, and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol 2007 ; 7 : 11. [CrossRef] [PubMed] [Google Scholar]
  15. Lauria G, Morbin M, Lombardi R, et al. Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and in painful neuropathies. J Peripher Nervous Syst 2006 ; 11 : 262–271. [CrossRef] [Google Scholar]
  16. Zahner MR, Li DP, Chen SR, et al. Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J Physiol 2003 ; 551 : 515–523. [CrossRef] [PubMed] [Google Scholar]
  17. Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 2004 ; 142 : 1354–1360. [CrossRef] [PubMed] [Google Scholar]
  18. Kissin I. Vanilloids-induced conduction analgesia: selective, dose-dependent, long-lasting, with a low-level of potential neurotoxicity. Anesth Analg 2008 ; 107 : 271–281. [CrossRef] [PubMed] [Google Scholar]
  19. Walk D, Wendelschafer-Crabb G, Davey C, et al. Concordance between epidermal nerve fiber density and sensory examination in patients with symptoms of idiopathic small fiber neuropathy. J Neurol Sci 2007 ; 255 : 23–26. [CrossRef] [PubMed] [Google Scholar]
  20. Robbins WR, Staats PS, Levine J, et al. Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth Analg 1998 ; 86 : 579–583. [PubMed] [Google Scholar]
  21. Petsche U, Fleischer E, Lembeck F, et al. The effect of capsaicin application to a peripheral nerve on impulse conduction in functionally identified afferent nerve fibres. Brain Res 1983 ; 265 : 233–240. [CrossRef] [PubMed] [Google Scholar]
  22. Chung J, Lee K, Hori Y, et al. Effects of capsaicin applied to a peripheral nerve on the responses of primate spinothalamic tract cells. Brain Res 1985 ; 329 : 27–38. [CrossRef] [PubMed] [Google Scholar]
  23. Xu X, Farkas-szallasi T, Lundberg JM, et al. Effects of the capsaicin analogue resiniferatoxin on spinal notice mechanisms in the rat: behavioral, electrophysiological and in situ hybridization studies. Brain Res 1997 ; 752 : 52–60. [CrossRef] [PubMed] [Google Scholar]
  24. Kissin E. The effects of intraarticular resiniferatoxin in experimental knee-joint arthritis. Anesth Analg 2005 ; 101 : 1433–1439. [CrossRef] [PubMed] [Google Scholar]
  25. Luongo L, Costa B, D’Agostino B, et al. Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little effects on bronchopulmonary function and body temperatue. Pharmacol Res 2012 ; 66 : 243–250. [CrossRef] [PubMed] [Google Scholar]
  26. Wahl P, Foged C, Tullin S, et al. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol 2001 ; 59 : 9–15. [PubMed] [Google Scholar]
  27. Caterina MJ. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000 ; 288 : 306–313. [CrossRef] [PubMed] [Google Scholar]
  28. Gavva NR. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol Sci 2008 ; 29 : 550–557. [CrossRef] [PubMed] [Google Scholar]
  29. Lehto SG, Tamir R, Deng H, et al. Antihyperalgesic effects of (R, E)-N-(2-hydroxy-2, 3-dihydro-1H-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008 ; 326 : 218–229. [CrossRef] [PubMed] [Google Scholar]
  30. Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010 ; 17 : 1010–1018. [CrossRef] [PubMed] [Google Scholar]
  31. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 agonist) therapy of pain relief: farewell or revival? Clin J Pain 2008 ; 24 : 142–154. [CrossRef] [PubMed] [Google Scholar]
  32. Noto C, Pappagallo M, Szallasi A. NGX-4010, a hight-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr Opin Investig Drugs 2009 ; 10 : 702–710. [PubMed] [Google Scholar]
  33. Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nature Rev Drug Discov 2007 ; 6 : 357–372. [CrossRef] [PubMed] [Google Scholar]
  34. Remadevi R, Szallisi A. Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. IDrugs 2008 ; 11 : 120–132. [PubMed] [Google Scholar]
  35. Szallasi A, Blumberg P. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience 1989 ; 30 : 515–520. [CrossRef] [PubMed] [Google Scholar]
  36. Iadarola M, Mannes A. The vanilloid agonist resiniferatoxin for interventional-based pain control. Curr Topics Med Chem 2011 ; 11 : 2171–2179. [CrossRef] [Google Scholar]
  37. Ham BK, Kim JH, Oh MM, et al. Effects of combination treatment of intravesical resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial cystitis: a pilot study. Int Neurol J 2012 ; 16 : 41–46. [CrossRef] [Google Scholar]
  38. Sharif Naeini R, Ciura S, Bourque CW. Les TRPV, des canaux qui vous donne soif ! Med Sci (Paris) 2006 ; 22 : 1035–1037. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  39. Li S, Bode AM, Zhu F, et al. TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling. Carcinogenesis 2011 ; 32 : 779–785. [CrossRef] [PubMed] [Google Scholar]
  40. Leleu-Chavain N, Biot C, Chavatte P, Millet R. Du cannabis aux agonistes sélectifs du récepteur CB2 : des molécules aux nombreuses vertus thérapeutiques. Med Sci (Paris) 2013 ; 29 : 523–528. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.